4a7i › Citations

Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.

Nazaré M, Matter H, Will DW, Wagner M, Urmann M, Czech J, Schreuder H, Bauer A, Ritter K, Wehner V
Angew Chem Int Ed Engl 51 905-11 (2012)
Cited: 16 times
EuropePMC logo PMID: 22190348

Articles - 4a7i mentioned but not cited (1)

  1. Novel 2-aminobenzamides as potential orally active antithrombotic agents. Verma A, Giridhar R, Kanhed A, Sinha A, Modh P, Yadav MR. ACS Med Chem Lett 4 32-36 (2013)


Reviews citing this publication (4)

  1. Applying thermodynamic profiling in lead finding and optimization. Klebe G. Nat Rev Drug Discov 14 95-110 (2015)
  2. Contemporary developments in the discovery of selective factor Xa inhibitors: A review. Patel NR, Patel DV, Murumkar PR, Yadav MR. Eur J Med Chem 121 671-698 (2016)
  3. Fragment library design, synthesis and expansion: nurturing a synthesis and training platform. Ray PC, Kiczun M, Huggett M, Lim A, Prati F, Gilbert IH, Wyatt PG. Drug Discov. Today 22 43-56 (2017)
  4. Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence. Moreira-Filho JT, Silva AC, Dantas RF, Gomes BF, Souza Neto LR, Brandao-Neto J, Owens RJ, Furnham N, Neves BJ, Silva-Junior FP, Andrade CH. Front Immunol 12 642383 (2021)

Articles citing this publication (11)

  1. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, Ciulli A. Chem Biol 19 1300-1312 (2012)
  2. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. Fjellström O, Akkaya S, Beisel HG, Eriksson PO, Erixon K, Gustafsson D, Jurva U, Kang D, Karis D, Knecht W, Nerme V, Nilsson I, Olsson T, Redzic A, Roth R, Sandmark J, Tigerström A, Öster L. PLoS ONE 10 e0113705 (2015)
  3. Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction. Jaegle M, Steinmetzer T, Rademann J. Angew. Chem. Int. Ed. Engl. 56 3718-3722 (2017)
  4. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases. Furtmann N, Häußler D, Scheidt T, Stirnberg M, Steinmetzer T, Bajorath J, Gütschow M. Chemistry 22 610-625 (2016)
  5. β-D-glucosyl conjugates of highly potent inhibitors of blood coagulation factor Xa bearing 2-chorothiophene as a P1 motif. Lopopolo G, de Candia M, Panza L, Romano MR, Lograno MD, Campagna F, Altomare C. ChemMedChem 7 1669-1677 (2012)
  6. Impact of a Central Scaffold on the Binding Affinity of Fragment Pairs Isolated from DNA-Encoded Self-Assembling Chemical Libraries. Bigatti M, Dal Corso A, Vanetti S, Cazzamalli S, Rieder U, Scheuermann J, Neri D, Sladojevich F. ChemMedChem 12 1748-1752 (2017)
  7. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic. Zhang Z, Su P, Li X, Song T, Chai G, Yu X, Zhang K. Arch. Pharm. (Weinheim) 348 89-99 (2015)
  8. Pairwise binding competition experiments for sorting hub-protein/effector interaction hierarchy and simultaneous equilibria. Ravera E, Carlon A, Parigi G. J. Biomol. NMR 60 29-36 (2014)
  9. Peptide Tethering: Pocket-Directed Fragment Screening for Peptidomimetic Inhibitor Discovery. Modell AE, Marrone F, Panigrahi NR, Zhang Y, Arora PS. J Am Chem Soc 144 1198-1204 (2022)
  10. News President of the Gesellschaft Deutscher Chemiker: M. Urmann / Paul Karrer Medal: H. Waldmann / KCS-Wiley Young Chemist Award: Y. Lee and D.-H. Ko. Angew. Chem. Int. Ed. Engl. 57 383 (2018)
  11. Pushing the Ligand Efficiency Metrics: Relative Group Contribution (RGC) Model as a Helpful Strategy to Promote a Fragment "Rescue" Effect. Vásquez AF, González Barrios A. Front Chem 7 564 (2019)


Quick links